Kinaxis named a “Top Pick” for 2026 by this analyst

National Bank Financial analyst Richard Tse says accelerating fundamentals continue to support his positive view on Kinaxis (Kinaxis Stock Quote, Chart, News, Analysts, Financials TSX:KXS), reiterating the stock as one of his “Top Picks” for 2026 following strong fourth-quarter results.

In a March 5 bulletin, Tse reiterated his “Outperform” rating and $240.00 target

Tse said Kinaxis delivered solid Q4 performance, reporting revenue of $144.2-million, above both his $140.5-million estimate and the $139.9-million consensus forecast. Adjusted EBITDA came in at $37.6-million, slightly below his $38.3-million estimate but ahead of the $35.9-million Street consensus.

Annual recurring revenue reached $433-million, rising 18% year-over-year on a constant-currency basis and accelerating from 17% growth in the previous quarter. SaaS revenue increased 16% year-over-year in constant currency, also improving from the 15% growth recorded in Q3.

Tse said the results mark an encouraging start under newly appointed CEO Razat Gaurav, who joined the company in January and addressed investor concerns about artificial intelligence competition during the earnings call.

“We think Kinaxis made a convincing case for why it won’t easily be disrupted due to its proprietary models, workflows and data,” Tse wrote, adding that the company is pursuing incremental revenue opportunities through partnerships with emerging AI leaders such as OpenAI and Anthropic.

Kinaxis provides cloud-based software-as-a-service supply chain management tools and has been expanding its enterprise footprint. Tse said the company was already executing well under interim leadership before Gaurav’s arrival but expects further strategic progress under the new CEO.

“All in, we think the company was executing well… even before its new CEO Razat Gaurav started in January,” Tse said, adding that early discussions with the new chief executive suggest “another incremental step-up” in strategy that could drive additional growth and a higher valuation.

Tse summarized the quarter’s theme in one word: “Acceleration.”

He said scaling operational initiatives appear to be translating into growth as long enterprise sales cycles begin to convert. Large enterprise wins roughly doubled year-over-year in 2025, while expansion orders accounted for 55% of new business, with new applications representing more than half of expansion activity.

Tse forecasts Kinaxis will generate $161.0-million in Adjusted EBITDA on revenue of $628.3-million in fiscal 2026. He expects those figures to increase to $183.7-million in Adjusted EBITDA on revenue of $713.2-million in fiscal 2027.

 

-30-

Tagged with: kxs
Rod Weatherbie

Rod Weatherbie is a journalist based in Prince Edward Island. Since 2004, he has written extensively about the Canadian property and casualty insurance landscape. He was also a founder and contributing editor for a Toronto-based arts website and a PEI-based food magazine. His fiction and poetry have been featured in The Fiddlehead, The Antigonish Review, and Juniper.

Recent Posts

Canadian travelers continue to avoid the U.S., RBC notes

RBC economist Abbey Xu said Canadian travel demand is not weakening so much as shifting away from the United States and… [Read More]

4 hours ago

Enphase Energy is a buy, this analyst says

Roth Capital Markets analyst Philip Shen maintained his “Buy” rating and $55.00 target on Enphase Energy (Enphase Energy Stock Quote,… [Read More]

4 hours ago

This stock might be the best way to play AI, this investor says

On BNN Bloomberg Market Call on April 6, Scotia Wealth Management portfolio manager Stan Wong named Taiwan Semiconductor Manufacturing (Taiwan… [Read More]

4 hours ago

Zedcor is undervalued, this analyst says

Ventum Capital Markets analyst Amr Ezzat reiterated his “Buy” rating and $8.70 target on Zedcor (Zedcor Stock Quote, Chart, News,… [Read More]

3 days ago

Is NervGen Pharma still undervalued?

Research Capital analyst Andre Uddin maintained his “Speculative Buy” rating and US$ 5.50 target on NervGen Pharma (NervGen Pharma Stock Quote, Chart,… [Read More]

3 days ago

Perimeter Medical Imaging wins price target raise from this analyst

In an April 8 note, Paradigm Capital analyst Scott McAuley maintained his “Speculative Buy” rating on Perimeter Medical Imaging AI… [Read More]

3 days ago